Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI1: Phase 3 Study of Imsidolimab in Generalized Pustular Psoriasis
jRCT2041230033Phase 3Not yet recruiting
- Sponsor
- AnaptysBio, Inc.
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of imsidolimab in generalized pustular psoriasis (GPP) (3 arms), sponsored by AnaptysBio, Inc. Primary endpoint: GPPPGA 0/1 response at Week 4. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
imsidolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on jRCT2041230033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230033.